Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

Medicus Pharma Non-Binding LOI Values SkinJect At ~$135M Pre-Money In SPAC Deal With Unnamed SPAC; Sees Closing In H1 2027

Medicus Pharma Sees ‘Substantial Reduction’ In Operating Expenses In Coming Quarters; Q3 Opex $14.5M

Medicus Pharma Q3 Net Loss $15.2M vs $16.0M Prior; Cash $5.0M At Sept 30, Plus $8.1M Restricted

Medicus Pharma to Outline CD228V Co-Development Strategy as It Prioritizes Capital Allocation, While Pursuing Separate Public Listing for SkinJect and Seeking Partners to Develop Teverelix

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.